Riso Pharmaceuticals International
Bioadvantex
Urixin
Silexin
Biolyse
Paclitaxel
BioSyent Inc.
FeraMAX
Feldan
Glenwood
Helsinn
Gelclair
Klean-Prep
Nasaleze Ltd.
Nasaleze
Omega laboratories
Pamidronate
PISA
Serral Laboratories
Stella Pharmaceutical Canada Inc.
Kolik-Gripe Water
Unigene
Fortical
 
Klean-Prep

 

Klean-Prep® is a modern specialist product for the preparation of the colon prior to colonoscopy and X-ray examinations.
Klean-Prep® is a balanced mixture of polyethylene glycol 3350 (PEG 3350) and electrolytes which, added to water, produces a clear, colourless, iso-osmotic solution. It acts as a bowel cleansing agent and allows a total cleansing in 4 to 6 hours.
Klean-Prep® can be taken at home and thus reduces hospitalization and nursing time, it has a high cleansing success rate (95%) and is very well tolerated.
Helsinn acquired world-wide rights to Klean-Prep® excluding Canada from Helix Biopharma in 1990 and has then developed and licensed-out the product to a number of partners in Europe, North America, Latin America, Africa, Middle and Far East.
Klean-Prep® is presently marketed under the same brand name in more than 30 countries. In these markets, KleanPrep® has achieved excellent sales performances and it is among the leaders in bowel cleansing preparations, thanks to the top-quality characteristic of the product combined with partnerships with companies well introduced in hospitals and diagnostic centres.
Klean-Prep® is the only product of its class which provides patients with a most useful and easy-to-use shaker for the preparation and intake of the solution. Klean-Prep® is available in the following packs:
  • Four sachets in carton, shaker, transit pack (for mailing)
  • Two sachets for children use in shaker
  • Loose sachets carton (for hospitals)
  • Flavour sachets available separately

 
 

Riso Pharma Tech is a Canadian-based specialty pharmaceutical company focused on in-licensing late-stage and approved molecules for marketing and sales in Canada, certain European Union countries, Latin America, and the Middle East.

 

From large multi-national pharmaceutical companies to small biotechs, Riso's license deals have yielded successful product launches in its territories. Five regional offices and over 360 employees worldwide enable Riso to extend the reach of our partner companies' products.

 

With an extensive track record of greater than 10+ years marketing and sales success in its territories, and thanks to Riso's financial strength, Riso is aggressively pursuing new in-licensing opportunities across several therapeutic areas: oncology, supportive care, neurology, endocrinology and women's health.